Table 5.
Minimum lethal doses for CTD and NCTD.
| IC90 (μM ) of CTD | (Ranking) | IC90 (μM ) of NCTD | (Ranking) | |
|---|---|---|---|---|
| Colon cancer cell line | ||||
| KM12 | 5 | (1) | 47 | (1) |
| HCT116 | 12 | (2) | 81 | (3) |
| SW620 | 18 | (3) | 90 | (4) |
| HT29 | 22 | (4) | 53 | (2) |
| HCC-2998 | 27 | (5) | 158 | (5) |
| HCT15 | 36 | (6) | 176 | (6) |
| Melanoma cancer cell line | ||||
| SK-MEL-2 | 6 | (1) | 16 | (1) |
| LOX-IMVI | 10 | (2) | 79 | (4) |
| MALME-3M | 16 | (3) | 120 | (7) |
| SK-MEL-5 | 22 | (4) | 92 | (5) |
| UACC-62 | 32 | (5) | 73 | (3) |
| UACC-257 | 33 | (6) | 129 | (8) |
| M14 | 35 | (7) | 43 | (2) |
| SK-MEL-28 | 41 | (8) | 92 | (5) |
| Renal cancer cell line | ||||
| TK-10 | 8 | (1) | 40 | (4) |
| RXF393 | 11 | (2) | 31 | (2) |
| ACHN | 15 | (3) | 72 | (6) |
| SN-12C | 17 | (4) | 33 | (3) |
| CAKI-1 | 17 | (4) | 16 | (1) |
| 786-0 | 18 | (6) | 77 | (7) |
| UO-31 | 34 | (7) | 87 | (8) |
| A498 | 39 | (8) | 63 | (5) |
| Prostate cancer cell line | ||||
| PC-3 | 11 | (1) | 13 | (1) |
| DU-145 | 18 | (2) | 63 | (2) |
| Ovarian cancer cell line | ||||
| OVCAR-3 | 4 | (1) | 64 | (2) |
| SK-OV-3 | 13 | (2) | 53 | (1) |
| IGR-OVI | 13 | (2) | 65 | (4) |
| OVCAR-4 | 21 | (4) | 64 | (2) |
| OVCAR-5 | 24 | (5) | 82 | (5) |
| OVCAR-8 | 31 | (6) | 114 | (6) |
| Breast cancer cell line | ||||
| MDA-MB-435 | 17 | (1) | 54 | (3) |
| BT-549 | 19 | (2) | 19 | (1) |
| HS-578T | 31 | (3) | 48 | (2) |
| MDA-MB-231 | 35 | (4) | 55 | (4) |
| T47-D | 37 | (5) | 127 | (6) |
| MDA-MB-468 | 123 | (6) | 70 | (5) |
| MCF-7 | 147 | (7) | 136 | (7) |
| CNS cancer cell line | ||||
| U251 | 7 | (1) | 34 | (2) |
| SNB-75 | 7 | (1) | 45 | (5) |
| SNB-19 | 9 | (3) | 40 | (3) |
| SF-268 | 16 | (5) | 30 | (1) |
| SF-295 | 34 | (6) | 73 | (6) |
| SF-539 | 38 | (7) | 40 | (3) |
| Lung cancer cell line | ||||
| EKVX | 12 | (1) | 45 | (1) |
| NCI-H322M | 16 | (2) | 48 | (2) |
| NCI-H460 | 17 | (3) | 56 | (4) |
| NCI/ADR-RES | 21 | (4) | 48 | (3) |
| A549 | 25 | (5) | 86 | (7) |
| HOP92 | 30 | (6) | 82 | (6) |
| NCI-H23 | 35 | (7) | 177 | (10) |
| HOP62 | 35 | (7) | 106 | (9) |
| NCI-H522 | 36 | (9) | 90 | (8) |
| NCI-H226 | 40 | (10) | 63 | (5) |
| Suspension cell line | ||||
| COLO-205 | 4 | (1) | 44 | (5) |
| K562 | 8 | (2) | 39 | (4) |
| CCRF-CEM | 12 | (3) | 29 | (3) |
| MOLT-4 | 16 | (4) | 12 | (1) |
| RPMI-8226 | 47 | (5) | 17 | (2) |
| Gastric cancer cell line | ||||
| MGC-803 | 8 | (1) | 74 | (4) |
| AGS | 8 | (1) | 34 | (2) |
| SGC-7901 | 10 | (3) | 29 | (1) |
| BGC 823 | 16 | (4) | 36 | (3) |
| Hepatoma cell line | ||||
| HepG2 | 5 | (1) | 55 | (7) |
| Hep3B | 7 | (2) | 44 | (5) |
| Huh7 | 8 | (3) | 43 | (3) |
| LM9 | 12 | (4) | 49 | (6) |
| SNU-449 | 12 | (4) | 35 | (1) |
| SNU-387 | 13 | (6) | 39 | (2) |
| SMMC7721 | 13 | (6) | 43 | (3) |
| Cholangiocarcinoma cell line | ||||
| RBE | 6 | (1) | 58 | (2) |
| QBC939 | 9 | (2) | 53 | (1) |
| HCCC9810 | 9 | (2) | 65 | (3) |